Intravenous products: News Medical report “Stealth Therapeutics Inc. announced today that its Invisiport has been implanted in a patient for the first time. Rachel, an 18 year-old from northern California, recently received an Invisiport to help with the treatment of her dysmotility syndrome. Dysmotility syndrome affects a person’s ability to digest certain foods requiring intravenous nutrition. Rachel is able to access her Invisiport two times per week on her own to provide the necessary intravenous nutrition required to treat her condition.
The Invisiport offers a microinvasive, patient-friendly alternative to traditional chest ports and peripherally inserted central catheters (PICCs). It is intended to be used in patients suffering from diseases that require long-term intravenous treatment, such as cancer, cystic fibrosis, Lyme disease or infection. Prior to receiving an Invisiport, Rachel received her nutrition through a PICC. After enduring seven different PICCs during a period of 18 months, Rachel and her family sought a better alternative to improve her quality of life.”